Pacira BioSciences Reports Preliminary Total Revenue of $75.5 Million for Second Quarter of 2020 -- EXPAREL average daily sales return to year-over-year growth for month of June 2020 --

Pacira BioSciences Reports Preliminary

Total Revenue of $75.5 Million for Second Quarter of 2020

-- EXPAREL average daily sales return

to year-over-year growth for month of June 2020 --

Parsippany, NJ, July 6, 2020 - Pacira BioSciences, Inc.

(Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue

of $75.5 million for the second quarter of 2020, compared to $102.6 million for the second quarter of 2019. During the second quarter

of 2020, average daily sales of EXPAREL (bupivacaine liposome injectable suspension) were 30 percent, 81 percent and 107 percent

of the prior year for the months of April, May, and June, respectively. During the second quarter of 2020, the Company's

product sales were negatively impacted by the COVID-19 pandemic, which mandated significant postponement or suspension in the scheduling

of elective surgical procedures resulting from public health guidance and government directives. Elective surgery restrictions

began to lift on a state-by-state basis in April 2020.

"We are very encouraged by the rapid recovery and consistent

uptake in EXPAREL sales and ordering accounts on a weekly basis since the peak of the COVID-19 pandemic impact in April,"

said Dave Stack, chairman and chief executive officer of Pacira BioSciences. "Ambulatory surgical centers have quickly returned

to the operating room to accommodate patients who were required to wait for important surgical interventions during COVID-19-related

shutdowns. These customers have been key to our return to year-over-year growth and underscore our investment in working closely

with our anesthesia partners to broaden the use of long-acting EXPAREL regional approaches as a cornerstone for multimodal opioid-sparing

strategies that continue to enable the shift of inpatient procedures to the 23-hour stay environment."

Second Quarter Financial Highlights

The financial information included in this press release is

preliminary, unaudited and subject to adjustment. It does not present all information necessary for an understanding of the company's

second quarter financial results for 2020. Pacira expects to report its complete financial results for the second quarter and first

half of 2020 during the Company's conference call scheduled for August 2020.

About Pacira BioSciences

Pacira BioSciences, Inc. (Nasdaq: PCRX)

is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes

for health care practitioners and their patients. The company's long-acting local analgesic, EXPAREL (bupivacaine

liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam ,

a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases

them over a desired period of time. In April 2019, Pacira acquired the iovera system, a handheld cryoanalgesia device

used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the

corporate mission to reduce overreliance on opioids, visit www.pacira.com.

EXPAREL (bupivacaine liposome injectable

suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene

brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other

nerve blocks. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over

a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the

peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing

significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of

the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.

Important Safety Information for Patients

EXPAREL should not be used in obstetrical paracervical

block anesthesia. In studies where EXPAREL was injected into the wound, the most common side effects were nausea, constipation,

and vomiting. In studies where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation.

EXPAREL is not recommended to be used in patients younger than 18 years old or in pregnant women. Tell your healthcare provider

if you have liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from your body.

EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL: can affect your nervous system

and your cardiovascular system; may cause an allergic reaction; may cause damage if injected into your joints.

The iovera system is used to destroy tissue during surgical

procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of

cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis

of the knee for up to 90 days. In one study, the majority of the patients suffering from osteoarthritis of the knee experienced

pain and system relief beyond 150 days.1 The iovera system's "1 90" Smart Tip configuration

(indicating one needle which is 90 mm long) can also facilitate target nerve location by conducting electrical nerve stimulation

from a separate nerve stimulator. The iovera system is not indicated for treatment of central nervous system tissue.

Important Safety Information

The iovera system is contraindicated for use in patients

with the following: Cryoglobulinemia; Paroxysmal cold hemoglobinuria; cold urticaria; Raynaud's disease; open and/or infected

wounds at or near the treatment line. Potential complications: As with any surgical treatment that uses needle-based therapy, there

is potential for temporary site-specific reactions, including but not limited to: bruising (ecchymosis); swelling (edema); inflammation

and/or redness (erythema); pain and/or tenderness; altered sensation (localized dysesthesia). Typically, these reactions resolve

with no physician intervention. Patients may help the healing process by applying ice packs to the affected sites, and by taking

over-the-counter analgesics.

Forward-Looking Statements

Any statements in this press release about the company's

future expectations, plans, outlook, projections and prospects, and other statements containing the words "believes,"

"anticipates," "plans," "estimates," "expects," "intends," "may,"

"will," "would," "could," "can" and similar expressions, constitute forward-looking

statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from

those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the impact

of the worldwide COVID-19 (Coronavirus) pandemic and related global economic conditions; the success of the company's sales

and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL;

the size and growth of the potential markets for EXPAREL and the company's ability to serve those markets; the company's

plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical

trials; the ability to realize anticipated benefits and synergies from the acquisition of MyoScience; the ability to successfully

integrate iovera and any other future acquisitions into the company's existing business; the commercial success

of iovera and other factors discussed in the "Risk Factors" of the company's most recent Annual Report

on Form 10-K and in other filings that the company periodically makes with the SEC. In addition, the forward-looking statements

included in this press release represent the company's views as of the date of this press release. Important factors could

cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such the company

anticipates that subsequent events and developments will cause its views to change. However, while the company may elect to update

these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking

statements should not be relied upon as representing the company's views as of any date subsequent to the date of this press

1Radnovich, R. et al. "Cryoneurolysis to treat

the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial." Osteoarthritis

and Cartilage (2017) p1-10.

Susan Mesco, (973) 451-4030

Coyne Public Relations

Alyssa Schneider, (973) 588-2270